Workflow
佰泽医疗通过港交所聆讯 专注于提供肿瘤全周期医疗服务
Zhi Tong Cai Jing·2025-06-07 23:44

Core Insights - Baize Medical is a service provider in the "full-cycle cancer medical services" sector, focusing on screening, diagnosis, treatment, and rehabilitation for cancer patients [2] - The company operates eight hospitals across several provinces in China, with a strong emphasis on providing comprehensive cancer care [2] - The private oncology medical service market in China has shown significant growth, with a projected increase in market size from approximately RMB 530 billion in 2022 to about RMB 1,092 billion by 2026 [4] Company Overview - Baize Medical offers a range of services including cancer diagnosis, treatment, rehabilitation, and health management for both patients and their families [2] - As of June 4, 2025, the company manages six private for-profit hospitals and two private non-profit hospitals, enhancing its market position [2] - The flagship hospital, Beijing Jingxi Cancer Hospital, has established a strong reputation in oncology [2] Market Dynamics - The annual compound growth rate of new cancer cases in China from 2018 to 2022 was approximately 2.9%, with about 4.8 million new cases reported in 2022 [4] - The private oncology medical service market in China has grown from approximately RMB 291 billion in 2018 to RMB 530 billion in 2022, reflecting a compound annual growth rate of about 16.2% [4] Financial Performance - Baize Medical's revenue increased from RMB 802.7 million in 2022 to RMB 1,072.2 million in 2023, and further to RMB 1,188.8 million in 2024, representing a compound annual growth rate of 21.7% [5][8] - The company's gross profit rose from RMB 79.6 million in 2022 to RMB 178.2 million in 2023, and to RMB 208.2 million in 2024, with a compound annual growth rate of 61.8% [5][8]